Evidence map›Paper›PMID 32558897›Full record

Trial reportThe Journal of experimental medicine2020

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.

Matthew J Frank, Michael S Khodadoust, Debra K Czerwinski, Ole A W Haabeth, Michael P Chu, David B Miklos, Ranjana H Advani, Ash A Alizadeh, Neel K Gupta, Lauren S Maeda and 14 more

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00490529 phase2completednot on this map

Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for Mantle Cell Lymphoma

TypeinterventionalSponsorRonald LevyRan2009 to 2017Enrolled59ConditionsLymphoma, Mantle-CellArmsCpG-MCL vaccine, PF-3512676, Vaccine-primed T-cells, Autologous hematopoietic stem cell transplant (HSCT), Rituximab
NCT07567222 phase1recruitingnot on this mapstarted 2026, after this paper: background citation

Safety, Tolerability, and Preliminary Antitumor Activity of Novel Therapeutic Tumor Vaccines in Advanced Solid Tumors

TypeinterventionalSponsorWest China HospitalRan2026 to 2027Enrolled54ConditionsMalignant TumorArmsYMN101, YMN102, YMN103, YMN104, YMN105
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Tumor vaccines: Toward multidimensional anti-tumor therapies.Human vaccines & immunotherapeutics · 2023
    Review
  5. Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Vaccinating against cancer: getting to prime time.Journal for immunotherapy of cancer · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Beneficial autoimmunity improves cancer prognosis.Nature reviews. Clinical oncology · 2021
    Review
  18. Therapeutic cancer vaccines.Nature reviews. Cancer · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Matthew J FrankDivision of Oncology, Stanford University, Stanford, CA.
Michael S KhodadoustDivision of Oncology, Stanford University, Stanford, CA.
Debra K CzerwinskiDivision of Oncology, Stanford University, Stanford, CA.
Ole A W HaabethDivision of Oncology, Stanford University, Stanford, CA.
Michael P ChuDepartment of Oncology, University of Alberta, Edmonton, Alberta, Canada.
David B MiklosDivision of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA.
Ranjana H AdvaniDivision of Oncology, Stanford University, Stanford, CA.
Ash A AlizadehDivision of Oncology, Stanford University, Stanford, CA.
Neel K GuptaDivision of Oncology, Stanford University, Stanford, CA.
Lauren S MaedaDivision of Oncology, Stanford University, Stanford, CA.
Sunil A ReddyDivision of Oncology, Stanford University, Stanford, CA.
Ginna G LaportDivision of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA.
Everett H MeyerDivision of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA.
Robert S NegrinDivision of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA.
Andrew R RezvaniDivision of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA.
Wen-Kai WengDivision of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA.
Kevin SheehanDivision of Oncology, Stanford University, Stanford, CA.
Malek FahamAdaptive Biotechnologies, Seattle, WA.
Ami OkadaDivision of Oncology, Stanford University, Stanford, CA.
A Holliston MooreDivision of Oncology, Stanford University, Stanford, CA.
Destiny L PhillipsDivision of Oncology, Stanford University, Stanford, CA.
Irene L WapnirDepartment of Surgery, Stanford University Healthcare, Stanford, CA.
Joshua D BrodyIcahn School of Medicine at Mount Sinai, New York, NY.
Ronald LevyDivision of Oncology, Stanford University, Stanford, CA.
Stanford University · USAdaptive Biotechnologies (United States) · USIcahn School of Medicine at Mount Sinai · USStanford Health Care · USUniversity of Alberta · CA

Funding

TUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos · 1989 to 2026
$73.3M
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the HostR35CA197353 · NCI · STANFORD UNIVERSITY · PI LEVY, RONALD · 2016 to 2022
$6.1M
NCI NIH HHS P01 CA049605NCI NIH HHS R35 CA197353
6 · The paper itself

Abstract

Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after immunochemotherapy, were vaccinated with irradiated, CpG-activated tumor cells. Subsequently, vaccine-primed lymphocytes were collected and reinfused after a standard autologous stem cell transplantation (ASCT). The primary endpoint was detection of minimal residual disease (MRD) within 1 yr after ASCT at the previously validated threshold of ≥1 malignant cell per 10,000 leukocyte equivalents. Of 45 evaluable patients, 40 (89%) were found to be MRD negative, and the MRD-positive patients experienced early subsequent relapse. The vaccination induced antitumor CD8 T cell immune responses in 40% of patients, and these were associated with favorable clinical outcomes. Patients with high tumor PD-L1 expression after in vitro exposure to CpG had inferior outcomes. Vaccination with CpG-stimulated autologous tumor cells followed by the adoptive transfer of vaccine-primed lymphocytes after ASCT is feasible and safe.

Indexed as

ImmunityAdultAgedB7-H1 AntigenCancer VaccinesCD8-Positive T-LymphocytesCell Line, TumorEndpoint DeterminationFemaleHumansImmunologic MemoryKaplan-Meier EstimateLymphoma, Mantle-CellMaleMiddle AgedNeoplasm, ResidualB7-H1 AntigenCancer VaccinesCD274 protein, humanOligodeoxyribonucleotidesProMune

Identifiers

PMID32558897
PMCPMC7478738
OpenAlexW3036060143

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.